Ohad Hammer

Ohad joined Pontifax in 2009 and is involved in identifying as well as evaluating new investment opportunities. Ohad focuses on early-stage projects and oversees scouting, due diligence, and company formation. He also supports development and business development activities within our early-stage portfolio companies. Ohad serves as a director in Metabomed, Pi Therapeutics, Eyevensys, and Precirix (formerly Camel-IDS). Ohad obtained his M.S. in Biology from Tel-Aviv University and writes about small and mid-cap biotech stocks on his blog: www.orf-blog.com